

Impact Factor: 5.878

ISSN: 2181-0990
DOI: 10.26739/2181-0990
www.tadqiqot.uz

JRHUNR

JOURNAL OF REPRODUCTIVE HEALTH AND URO-NEPHROLOGY RESEARCH



TADQIQOT.UZ

VOLUME 3,
ISSUE 1

2022

МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ
РЕСПУБЛИКИ УЗБЕКИСТАН

Журнал репродуктивного здоровья и уро-
нефрологических исследований

JOURNAL OF REPRODUCTIVE HEALTH AND URO-NEPHROLOGY RESEARCH

Главный редактор: Б.Б. НЕГМАДЖАНОВ

Учредитель:

Самаркандский государственный
медицинский институт

Tadqiqot.uz

Ежеквартальный
научно-практический
журнал

№ 1
2022

ISSN: 2181-0990
DOI: 10.26739/2181-0990

Главный редактор:
Chief Editor:

Негмаджанов Баходур Болтаевич
доктор медицинских наук, профессор,
заведующий кафедрой Акушерства и гинекологии №2
Самаркандского Государственного медицинского института

Doctor of Medical Sciences, Professor,
Head of the Obstetrics and Gynecology Department
№. 2 of the Samarkand State Medical Institute

Заместитель главного редактора:
Deputy Chief Editor:

Каттаходжаева Махмуда Хамдамовна
доктор медицинских наук, профессор
Кафедры Акушерства и гинекологии Ташкентского
Государственного стоматологического института

Doctor of Medical Sciences, Professor
Departments of Obstetrics and Gynecology
Tashkent State Dental Institute

ЧЛЕНЫ РЕДАКЦИОННОЙ КОЛЛЕГИИ:
MEMBERS OF THE EDITORIAL BOARD:

Луис Альфондо де ла Фуэнте Эрнандес
профессор, член Европейского общества
репродукции человека и эмбриологии
Prof. Medical Director of the Instituto
Europeo de Fertilidad. (Madrid, Spain)

Ramašauskaitė Diana
профессор и руководитель клиники акушерства
и гинекологии при институте клинической
медицины Вильнюсского университета (Prof. Clinic
of Obstetrics and Gynecology Vilnius University Faculty
of Medicine, Latvia)

Зуфарова Шахноза Алимджановна
доктор медицинских наук, профессор, директор
Республиканского центра репродуктивного
здоровья населения (M.D., Professor, Director
of the Republican Center for Reproductive Health)

Агабабян Ирина Рубеновна
Кандидат медицинских наук, доцент, Самаркандского
Государственного медицинского института
(Candidate of Medical Sciences, Associate Professor,
Samarkand State Medical Institute)

Зокирова Нодира Исламовна
доктор медицинских наук, профессор Самаркандского
Государственного медицинского института

Кадыров Зиёратшо Абдуллоевич
доктор медицинских наук, профессор
Непрерывного медицинского образования
медицинского института РУДН.

Негматуллаева Мастура Нуруллаевна
доктор медицинских наук, профессор Бухарского
государственный медицинского института.

Окулов Алексей Борисович
доктор медицинских наук, профессор
Московского государственного
медико-стоматологического университета.

Махмудова Севара Эркиновна
доктор философии по медицинским наукам (PhD)
(ответственный секретарь)

ЧЛЕНЫ РЕДАКЦИОННОГО СОВЕТА:
MEMBERS OF THE EDITORIAL BOARD:

Boris Chertin
MD Chairman, Departments of Urology & Pediatric
Urology, Shaare Zedek Medical Center, Clinical Professor in
Surgery/Urology, Faculty of Medicine, Hebrew University,
Jerusalem. (Профессор хирургии/урологии, медицинский
факультета ивритского университета)

Fisun Vural
Doçent Bilimleri Üniversitesi, Haydarpaşa
Numune Eğitim ve Araştırma Hastanesi
Kadın Hastalıkları ve Doğum Kliniği İdari
ve Eğitim Sorumlusu. Доцент Университета
естественных наук, учебно-исследовательской
больницы клиники акушерства и гинекологии.

Melike Betül Öğütmen
SBÜ Haydarpaşa Numune SUAM Nefroloji
Kliniği idari ve Eğitim Sorumlusu.
Доцент Университета естественных наук,
учебно-исследовательской
больницы клиники нефрологии.

Аллазов Салах Алазович
доктор медицинских наук, профессор
кафедры урологии, Самаркандского
Государственного медицинского института

Ахмеджанова Наргиза Исмаиловна
доктор медицинских наук, доцент,
заведующая кафедрой №2 педиатрии с
курсом неонатологии, Самаркандского
Государственного медицинского института

Локшин Вячеслав Нотанович
доктор медицинских наук, профессор,
член-корр. НАН РК, президент Казахстанской
ассоциации репродуктивной медицины.

Никольская Ирина Георгиевна
доктор медицинских наук, профессор
ГБУ МО МОНИАГ.

Шалина Раиса Ивановна
доктор медицинских наук, профессор
кафедры акушерства и гинекологии педиатрического
факультета РНИМУ им.Н.И.Пирогова

ОРИГИНАЛЬНЫЕ СТАТЬИ

- 1. Абдурахманова С. И., Сулейманова Н. Ж., Ходжаева З. А., Назарова Д. Г.**
ОСОБЕННОСТИ УЛЬТРАЗВУКОВЫХ И ДОППЛЕРОМЕТРИЧЕСКИХ ИЗМЕНЕНИЙ У ЖЕНЩИН С МИОМОЙ МАТКИ И / ИЛИ АДЕНОМИОЗОМ И ИХ РОЛЬ В ВЫБОРЕ МЕТОДА ЛЕЧЕНИЯ / FEATURES OF ULTRASOUND AND DOPPLEROMETRIC CHANGES IN WOMEN WITH UTERINE FIBROUS AND / OR ADENOMIOSIS AND THEIR ROLE IN THE CHOICE OF TREATMENT METHOD/BACHADON MIOMASI VA / YOKI ADENOMIOZLI AYOLLARDA ULTRATOVUSH VA DOPPLEROMETRIYADAGI O'ZGARISHLAR, HAMDA ULARNING DAVO CHORALARINI TANLASHDAGI O'RNI.....44
- 2. Ахматова Ю. А., Ахмеджанова Н. И., Ахматов А.**
КЛИНИКО-ДИАГНОСТИЧЕСКОЕ ЗНАЧЕНИЕ НАРУШЕНИЯ БЕЛКОВОГО МЕТАБОЛИЗМА У ДЕТЕЙ С ХРОНИЧЕСКИМ ТУБУЛОИНТЕРСТИЦИАЛЬНЫМ НЕФРИТОМ / CLINICAL AND DIAGNOSTIC SIGNIFICANCE OF PROTEIN METABOLISM DISORDERS IN CHILDREN WITH CHRONIC TUBULOINTERSTITIAL NEPHRITIS / SURUNKALI TUBULOINTERSTITIAL NEFRITGA CHALINGAN BOLALARDA OQSILLAR METABOLIZMI BUZILISHINING KLINIK-DIAGNOSTIK AHAMIYATI.....48
- 3. Ахмеджанова Н. И., Ахмеджанов И. А., Ашурова Н. Ш.**
КЛИНИЧЕСКИЕ ОСОБЕННОСТИ ХРОНИЧЕСКОГО ГЛОМЕРУЛОНЕФРИТА У ДЕТЕЙ / CLINICAL FEATURES OF CHRONIC GLOMERULONEFRITIS IN CHILDREN/BOLALARDA SURUNKALI GLOMERULONEFRITNING KLINIK XUSUSIYATLARI.....53
- 4. Мамаджанова Ш.К.**
РОЛЬ МИО-ИНОЗИТОЛА В ЛЕЧЕНИИ БЕСПЛОДИЯ У ПАЦИЕНТОК С СИНДРОМОМ ПОЛИКИСТОЗНЫХ ЯИЧНИКОВ / THE ROLE OF MYO-INOSITOL IN TREATING INFERTILITY AMONG PATIENTS WITH POLYCYSTIC OVARY SYNDROME / TUXUMODON POLIKISTOZ SINDROMI BO'LGAN BEMORLARDA BEPUSHTLIKNI DAVOLASHDA MYO-INOSITOLNING O'RNI.....57
- 5. Негмаджанов Б. Б., Махмудова С. Э.**
ПЛАЦЕНТАРНЫЙ ФАКТОР РОСТА И SFLT-1(ФМС-ПОДОБНАЯ ТИРОЗИНКИНАЗА) КАК ПРЕДИКТОР ОСЛОЖНЕНИЙ ПРИ ПРЕКЛАМПСИИ/PLACENTAL GROWTH FACTOR AND SFLT-1 (FMS-LIKE TYROSINE KINASE) AS A PREDICTOR OF COMPLICATIONS IN PRECLAMPSIA / PLATSENTAL O'SISH FAKTORI VA SFLT-1 (FMSGA O'XSHASH TYROZINKINAZA) PREEKLAMPSIYA ASORATLARINI BASHORAT QILUVCHI PREDIKTOR.....60
- 6. Фазылбеков Р. А., Каттаходжаева М.Х., Сулейманова Н. Ж., Абдурахманова С. И.**
ЗНАЧЕНИЕ НОВЫХ ПОДХОДОВ В ДИАГНОСТИКЕ И ЛЕЧЕНИИ ГНОЙНО-ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ПРИДАТКОВ МАТКИ / IMPORTANCE OF MODERN APPROACHES IN THE DIAGNOSIS OF PURULENT-INFLAMMATORY DISEASES OF THE UTERUS / BACHADON ORTIQLARI YIRINGLI –YALLIG'LANISH KASALLIKLARI DIAGNOSTIKASIDA ZAMONAVIY YONDOSHISHLARNING AHAMIYATI.....65




УДК:618.11-006.2-031

Мамаджанова Шахноз Кахрамоновна
Старший преподаватель
Андижанский Государственный
Медицинский институт, Андижан, Узбекистан

РОЛЬ МИО-ИНОЗИТОЛА В ЛЕЧЕНИИ БЕСПЛОДИЯ У ПАЦИЕНТОК С СИНДРОМОМ ПОЛИКИСТОЗНЫХ ЯИЧНИКОВ

For citation: Mamadjanova Shakhnoz Kahramonovna, The role of myo-inositol in treating infertility among patients with polycystic ovary syndrome, Journal of reproductive health and uro-nephrology research. 2022, vol. 3, issue 1, pp. 57-59

 <http://dx.doi.org/10.5281/zenodo.6426646>

АННОТАЦИЯ

Синдром поликистозных яичников (СПКЯ) является широко распространенным заболеванием, представляющим собой единственное наиболее распространенное эндокринно-метаболическое расстройство у женщин репродуктивного возраста. СПКЯ отмечается в 30-40% случаев резистентностью к инсулину и гиперандрогенией. Было отмечено, что мио-инозитол повышает чувствительность к инсулину, снижает гиперандрогению и улучшает менструальный цикл. Мы провели исследование влияния мио-инозитола на СПКЯ, и он показал высокую эффективность в нормализации функции яичников и созревании ооцита и впоследствии возникновении беременности.

Ключевые слова: синдром поликистозных яичников, мио-инозитол, чувствительность к инсулину, гиперандрогения, дисменорея.

Mamadjanova Shakhnoz Kahramonovna
Senior Lecturer Andijan State
Medical Institute, Andijan, Uzbekistan.

THE ROLE OF MYO-INOSITOL IN TREATING INFERTILITY AMONG PATIENTS WITH POLYCYSTIC OVARY SYNDROME

ABSTRACT

Polycystic ovary syndrome (PCOS) is a highly prevalent disorder, representing the single most common endocrine-metabolic disorder in reproductive-aged women. PCOS is marked in 30 to 40% by insulin resistance and hyperandrogenism. Myo-inositol was noted to increase insulin sensitivity, decrease hyperandrogenism and improve the menstrual cycle. We conducted a research on the impact of Myo-inositol administration in PCOS and it marked a high effectiveness in normalizing ovarian function and maturing the oocyte and leading to pregnancy.

Key words: polycystic ovarian syndrome, myo-inositol, insulin sensitivity, hyperandrogenism, dysmenorrhea

Mamadjanova Shakhnoz Kahramonovna
Katta o'qituvchi Andijan davlat
tibbiyot instituti, Andijan, O'zbekiston

TUXUMODON POLIKISTOZ SINDROMI BO'LGAN BEMORLARDA BEPUSHTLIKNI DAVOLASHDA MYO-INOSITOLNING O'RNI

ANNOTATSIYA

Tuxumdon Polikistoz sindromi juda keng tarqalgan kasallik bo'lib, reproduktiv yoshdagi ayollarda eng ko'p uchraydigan endokrin-metabolik kasallikdir. Polikistik tuxumdon sindromi 30-40% insulin sezuvchanlik va giperandrogenizm bilan belgilanadi. Miyo-inozitol insulinga sezgirlikni oshiradi, giperandrogenizmi kamaytiradi va hayz davrini yaxshilaydi. Biz Myo-inozitolni polikistik tuxumdon sindromiga ta'siri bo'yicha tadqiqot o'tkazdik va bu tuxumdonlar faoliyatini normalashtirish va oositni yetishtirishda yuqori samaradorlikni ko'rsatdi va keyinchalik homiladorlikka olib kelishi kuzatildi.

Kalit so'zlar: polikistik tuxumdon sindromi, mio-inozitol, insulin sezuvchanlik, giperandrogenizm, dismenoreya.

Introduction. Polycystic ovary syndrome is a highly inherited complex polygenic, multifactorial disorder. Pathophysiologically abnormalities in gonadotropin secretion or action, ovarian folliculogenesis, steroidogenesis, insulin secretion or action, and

adipose tissue function, among others, have been described in PCOS currently there are four recognized phenotypes of PCOS:

1) hyperandrogenism+oligo-anovulation+polycystic ovarian morphology;

- 2) hyperandrogenism+oligo-anovulation;
- 3) hyperandrogenism+polycystic ovarian morphology; and
- 4) oligo-anovulation+polycystic ovarian morphology, each with different long-term health and metabolic implications. [2]

Polycystic ovary syndrome (PCOS) is the most common cause of ovulation disorders, hyperandrogenism and infertility due to ovulatory dysfunction, affecting more than 7% of childbearing age women. as previously mentioned, PCOS is associated with insulin resistance in 30–40% of cases. Hyperglycemia inhibits hepatic production of Sex Hormone Binding Globulin (SHBG), which leads to an increase of free androgens in the blood circulation, and insulin resistance increases the production of androgens by the theca cells. The management of this insulin resistance is therefore essential in the treatment of PCOS, and is based on nutritional rules, physical activity and other molecules including myo-inositol (MI).

The purpose of research: To check the efficiency of myo-inositol (Inotir in our case) in treating infertility among women with polycystic ovarian syndrome.

Materials and methods of research:

Complex observation of a group of women (the age within 20-30 years) were positively tested on having the polycystic ovarian syndrome. The group included 52 patients of Andijan Regional Perinatal Centre with hyperandrogenism(detected via clinical and biochemical analysis), oligo-anovulation and polycystic ovarian morphology(detected via ultrasound diagnostics or tests of functional diagnostics) suffering from infertility.

Results and discussion:

Inositol is a polyalcohol of which there are nine stereoisomers (cyclohexane-1,2,3,4,5,6-hexol). Two of them have been shown to

mediate the post-receptor effects of insulin: myo-inositol (MI-cis-1,2,3,5-trans-4,6-cyclohexanehexol) and D-chiro-inositol (DCI-cis-1,2,4-trans-3,5,6-cyclohexanehexol) (DCI). The food categories that contain the highest concentration of inositols are fruits, beans, corn and nuts. At the intestinal level, DCI negatively interferes with MI absorption. Uptake of free inositol by tissues occurs by a membrane dependent sodium inositol cotransporter. MI and DCI are controlled by some inositol phosphoglycans (IPGs), known as second messengers. These mediators are then internalized and modify enzymatic activity and intracellular metabolism, mimicking the action of insulin. When insulin binds to its receptor, these IPGs are generated by hydrolysis of glycosylphosphatidylinositol (GPI) lipids and/or specific proteins located on the outer part of the cell membrane. Two IPGs are formed: IPG-DCI (or IPG-P) and IPG-MI (or IPG-A). IPG-P will directly activate the glycogen synthase but will also indirectly activate it via the activation of phosphoprotein phosphatase 1 (PP1). IPG-A causes direct glucose uptake and inhibits cAMP protein kinase A and adenylate cyclase, thereby activating PP1. These effects allow a decrease in blood glucose levels (insulin-like effect), regardless of the signal passing through the insulin receptor [3]. In women with PCOS, impaired inositol and/or GPI metabolism contributes to insulin resistance, but obesity plays a specific role in abnormal IPG-P production independently of PCOS [3]. MI decreases body weight, leptin secretion and increases HDL cholesterol [4] Thanks to its antioxidant action (SOD, catalase and GSH increase), MI improves cell morphology and growth, as well as the synthesis of lipids participating in cell membranes. Figure 1 summarizes the different actions of MI in the ovary.




Fig.1 Roles of myo-inositol (MI) in the ovary (original figure from the author, after review of patho-physiologic effects of MI, DCI and others hormones on ovarian cells). MI: myo-inositol; DCI: D-chiro-inositol; (40:1): MI/DCI ratio; LHR: LH receptor; PKA: protein kinase A; P: progesterone; T: testosterone; INs: insulin; InsR: insulin receptor; bm: basalis membrane; PIP: phospho inositide phosphate; IP3: inositide triphosphate; AMH: anti-Müllerian hormone; E2: estradiol; + : stimulating effect

In PCOS, early follicular growth is excessive, but subsequent progression to a dominant follicle is interrupted (follicular arrest). Intraovarian androgens have been implicated in the excess of follicles and the elevated serum estradiol levels. This increased production of androgens is an inherent property of thecal cells, but it is increased by the surplus of LH and by hyperinsulinism. In women with PCOS, treatment with metformin (MET) ameliorated the insulin sensitivity and decreased the androgens levels, but the limitations to MET use are its gastrointestinal side effects. In this case of PCOS, the place of MI was evaluated. Studies show that MI leads to a decrease in LH and androgen

levels, as well as a decrease in insulin resistance. Thus, MI is believed to be able to re-establish ovulatory menstrual cycles (especially in obese women with PCOS).

As a result, in our research with PCOS patients, after administering drug INOTIR 3g twice a day these changes were noted:

1. Relative lowering of blood insulin levels
 2. Decreased testosterone concentration
 3. Increase in number of globulins binding sex hormones after administering the drug during 24 weeks and more.
- And occurrence of pregnancy due to symptomatic refinement.

Conclusion.

Polycystic ovarian syndrome is a highly inherited complex polygenic, multifactorial disorder. Pathophysiological abnormalities in gonadotropin secretion or action, ovarian folliculogenesis, steroidogenesis, insulin secretion or action, and adipose tissue function, among others, have been described in PCOS. Insulin resistance

increases the production of androgens by the theca cells. Elevated androgen levels play a significant role in menstrual cycle disturbance and anovulation. These factors then become obstacles in occurrence of pregnancy. Myo-inositol (MI) increases insulin sensitivity, decreases hyperandrogenism and improves the menstrual cycle as a result leading to pregnancy.

List of references:

1. Merviel P, Bouée S, Ménard M, Le Martelot MT, Roche S, Lelièvre C, et al. Which ovarian stimulation to which women: the polycystic ovary syndrome (PCOS). *Gynecol Obstet Fertil Senol.* 2017;45:623–31.
2. Chiu TTY, Rogers MS, Law ELK, Britton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF : relationship with oocyte quality. *Hum Reprod.* 2002;17:1591–6.
3. Lagana AS, Garzon S, Casarin J, Franchi M, Ghazzi F. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach. *Trends Endocrinol Metab.* 2018;29:768–80.
4. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double-blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. *Eur Rev Med Pharmacol Sci.* 2007;11:347–54.